GOSS icon

Gossamer Bio

1.31 USD
+0.00
0.00%
At close Feb 14, 4:00 PM EST
After hours
1.33
+0.02
1.53%
1 day
0.00%
5 days
24.76%
1 month
54.41%
3 months
70.13%
6 months
58.40%
Year to date
35.05%
1 year
35.41%
5 years
-91.00%
10 years
-92.70%
 

About: Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.

Employees: 135

0
Funds holding %
of 6,831 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

70% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 10

36% more call options, than puts

Call options by funds: $785K | Put options by funds: $579K

6% more funds holding

Funds holding: 94 [Q2] → 100 (+6) [Q3]

5% more capital invested

Capital invested by funds: $166M [Q2] → $173M (+$7.57M) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]

3.71% less ownership

Funds ownership: 81.21% [Q2] → 77.51% (-3.71%) [Q3]

19% less repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 31

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$10
663%
upside
Avg. target
$10
663%
upside
High target
$10
663%
upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Patrick Trucchio
40% 1-year accuracy
70 / 173 met price target
663%upside
$10
Buy
Reiterated
30 Jan 2025

Financial journalist opinion

Based on 4 articles about GOSS published over the past 30 days

Neutral
Seeking Alpha
2 days ago
Gossamer Bio Is A Good Speculative Buy On Seralutinib For PAH And PH-ILD
Gossamer Bio develops Seralutinib, which is basically an inhaled TKI that targets vascular remodeling, inflammation, and fibrosis. This makes it ideal for treating PAH and PH-ILD. GOSS has so far produced encouraging Phase 2 data and has an ongoing Phase 3 PROSERA trial for PAH. The main event comes with its topline results in Q4 2025. GOSS's pipeline includes a PH-ILD program slated to start Phase 3 in mid-2025. This program addresses a larger, high-mortality TAM.
Gossamer Bio Is A Good Speculative Buy On Seralutinib For PAH And PH-ILD
Neutral
Business Wire
1 week ago
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer's Board of Directors approved the grant, effective February 5, 2025, to three non-executive employees of non-qualified stock option.
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Neutral
Business Wire
1 week ago
Gossamer Bio Presented Clinical and Preclinical Data at the Pulmonary Vascular Research Institute 2025 Annual Congress
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), presented one oral presentation and three posters related to seralutinib at the Pulmonary Vascular Research Institute (PVRI) 2025 Annual Congress that took place January 29th through February.
Gossamer Bio Presented Clinical and Preclinical Data at the Pulmonary Vascular Research Institute 2025 Annual Congress
Neutral
Business Wire
2 weeks ago
Gossamer Bio to Present Clinical and Preclinical Data at the Pulmonary Vascular Research Institute 2025 Annual Congress
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced one oral and three poster presentations related to seralutinib at the Pulmonary Vascular Research Institute (PVRI) 2025 Annual Congress taking place January 29th through Febru.
Gossamer Bio to Present Clinical and Preclinical Data at the Pulmonary Vascular Research Institute 2025 Annual Congress
Neutral
Business Wire
1 month ago
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer's Board of Directors approved the grant, effective January 6, 2025, to three non-executive employees of non-qualified stock option.
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Positive
Zacks Investment Research
1 month ago
Gossamer Bio (GOSS) Upgraded to Buy: Here's What You Should Know
Gossamer Bio (GOSS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Gossamer Bio (GOSS) Upgraded to Buy: Here's What You Should Know
Positive
Zacks Investment Research
2 months ago
All You Need to Know About Gossamer Bio (GOSS) Rating Upgrade to Buy
Gossamer Bio (GOSS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
All You Need to Know About Gossamer Bio (GOSS) Rating Upgrade to Buy
Negative
Zacks Investment Research
3 months ago
After Plunging -20% in 4 Weeks, Here's Why the Trend Might Reverse for Gossamer Bio (GOSS)
Gossamer Bio (GOSS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
After Plunging -20% in 4 Weeks, Here's Why the Trend Might Reverse for Gossamer Bio (GOSS)
Negative
Zacks Investment Research
3 months ago
After Plunging -15.92% in 4 Weeks, Here's Why the Trend Might Reverse for Gossamer Bio (GOSS)
The heavy selling pressure might have exhausted for Gossamer Bio (GOSS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
After Plunging -15.92% in 4 Weeks, Here's Why the Trend Might Reverse for Gossamer Bio (GOSS)
Neutral
Business Wire
3 months ago
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer's Board of Directors approved the grant, effective November 8, 2024, to two new non-executive employees of non-qualified stock opti.
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Charts implemented using Lightweight Charts™